18% driven by temporary put Rare disease sales driven by global commercial execution Novo Nordisk ® Rare disease sales decrease is driven by: • 18% sales decline in North America Operations • 17% sales decline in International Operations Rare blood disorders sales decreased by 1%, driven by: • Lower sales of NovoSeven ® partially countered by sales of haemophilia A and B products Rare endocrine disorders sales decreased by 46% driven by: • North America Operations sales for Norditropin ® declined by 45% reflecting a temporary reduction in manufacturing output and lower realised prices in the US • Novo Nordisk is the leading company in the global human growth disorder market with a value market share of ~29.5% peroct ® , Refixia ® and NovoThirteen ® ; 3 Primarily Norditropin ® ; nstant exchange rates
Download PDF file